Comment from Turner, Teresa
AnonymousSupportBusiness
Summary: A business owner (likely a veterinary clinic or pharmacy) argues that the current list of commercial products is insufficient for many patients due to issues with dosage forms, concentrations, and palatability. They support the proposed action to allow more bulk drug substances for compounding to ensure animals can receive timely and appropriate treatment.
•A significant percentage of my customers reject the commercial product.
•Only a very restricted range of low-concentration oral suspensions are currently permitted. This range of drugs is insufficient to meet the needs of animals who may require other dosage forms or strengths.
•Commercially available flavored suspensions may not be suitable to the palates of many animals, causing rejection of the medication and non-compliance.
•Tablet sizes of the commercial product are too large for many feline and small canine patients, resulting in compliance failure.
Animals left untreated while waiting 1-2 weeks for a patient-specific prescription will deteriorate as they experience unnecessary suffering, debilitation, and death.
Owners will have better compliance when products like this are readily available to treat their animals